Beijing Sinocelltech Group Ltd. (SHA: 688520) announced that SCT810 Injection has been approved by China’s National Medical Products Administration (NMPA) to initiate a Phase I/II clinical study in patients with moderate‑to‑severe hemophilia A (HA) or hemophilia B (HB), with or without inhibitors.
Contents
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Action | Approval to initiate a Phase I/II clinical study |
| Product | SCT810 Injection – anti‑TFPI monoclonal antibody |
| Indication | Moderate‑to‑severe hemophilia A or B, with or without inhibitors |
| Announcement Date | 13 Oct 2026 |
| Sponsor | Beijing Sinocelltech Group Ltd. (SHA: 688520) |
| Next Steps | Phase I/II enrollment and dose evaluation; sites and timelines Not disclosed |
Drug Profile & Mechanism of Action
- Molecule: SCT810, an anti‑tissue factor pathway inhibitor (TFPI) monoclonal antibody for the treatment of hemophilia A or hemophilia B.
- Factor‑Independent Mechanism: The mechanism of action does not depend on the activity of coagulation factor VIII (FVIII) or factor IX (FIX) – addressing the root limitation of conventional factor replacement therapy.
- Inhibitor‑Agnostic Activity: Efficacy is unaffected by the presence or absence of inhibitors, extending treatment potential to inhibitor‑positive patients who are poorly served by standard factor products.
- Hemostatic Rationale: Under conditions of FVIII or FIX deficiency, SCT810 improves coagulation function and promotes hemostasis by enhancing the activity of the extrinsic coagulation pathway – rebalancing hemostasis through TFPI blockade rather than replacing the missing factor.
- Optimized Profile: The optimized SCT810 is expected to provide hemophilia A or B patients a safer, more effective, longer‑dosing‑interval and more convenient prophylactic treatment option.
Clinical Study Snapshot
| Attribute | Detail |
|---|---|
| Study Phase | Phase I/II |
| Patient Population | Moderate‑to‑severe HA or HB, with or without inhibitors |
| Treatment Setting | Prophylactic therapy |
| Endpoints | Not disclosed |
| Enrollment / Timeline | Not disclosed |
Market Impact & Outlook
- Broad Dual‑Indication Reach: Unlike factor replacement products confined to a single hemophilia type, SCT810’s factor‑independent mechanism addresses both hemophilia A and hemophilia B in one molecule – with or without inhibitors – covering the full spectrum of moderate‑to‑severe patients.
- Inhibitor Population Unmet Need: Inhibitor development remains the most serious complication of factor replacement therapy; a mechanism unaffected by inhibitors directly targets this hard‑to‑treat, high‑burden subgroup.
- Prophylaxis Convenience: A longer dosing interval and more convenient administration profile could improve adherence versus frequent factor infusions – a decisive real‑world advantage in lifelong prophylaxis.
- TFPI Class Momentum: SCT810 positions Sinocelltech (SHA: 688520) within the emerging anti‑TFPI antibody class of hemophilia therapies, a validated rebalancing approach gaining global clinical traction.
- Domestic Hemophilia Care Gap: China’s diagnosed hemophilia population continues to expand, with prophylactic treatment penetration still limited relative to developed markets – a domestically developed, inhibitor‑agnostic prophylaxis option carries significant clinical and commercial relevance.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical trial progression, regulatory timelines and therapeutic potential of SCT810. Actual results may differ materially due to risks including early‑phase safety and efficacy outcomes, dose optimization in Phase I/II, competitive dynamics among non‑factor hemophilia therapies, and evolving NMPA review requirements.-Fineline Info & Tech
